Amundi Asset Management US’s BioMarin Pharmaceuticals BMRN Stock Holding History

Amundi Asset Management US’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$9.18M	Buy	121,581 +13,177	+12%	+$1.08M	0.01%	864
2020 Q4	$9.51M	Buy	108,404 +8,388	+8%	+$665K	0.01%	825
2020 Q3	$7.61M	Sell	100,016 -212,995	-68%	-$21.6M	0.01%	791
2020 Q2	$38.6M	Buy	313,011 +155,771	+99%	+$15.5M	0.05%	365
2020 Q1	$13.3M	Sell	157,240 -412,730	-72%	-$35.6M	0.02%	501
2019 Q4	$48.2M	Buy	569,970 +77,914	+16%	+$5.88M	0.06%	322
2019 Q3	$33.2M	Sell	492,056 -12,211	-2%	-$941K	0.05%	375
2019 Q2	$43.2M	Buy	504,267 +29,906	+6%	+$2.56M	0.04%	355
2019 Q1	$42.1M	Buy	474,361 +35,375	+8%	+$3.28M	0.06%	322
2018 Q4	$37.4K	Sell	438,986 -90,567	-17%	-$8.62M	0.03%	306
2018 Q3	$51.4M	Buy	529,553 +263,011	+99%	+$26.3M	0.07%	279
2018 Q2	$25.1M	Buy	266,542 +15,457	+6%	+$1.35M	0.04%	456
2018 Q1	$20.4M	Buy	251,085 +62,133	+33%	+$5.33M	0.03%	474
2017 Q4	$16.8M	Buy	+188,952	New	+$16.4M	0.03%	523

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amundi Asset Management US's BMRN Position: Q1 2021 in Review

Amundi Asset Management US increased its BioMarin Pharmaceuticals (BMRN) stake by 12% in Q1 2021, buying an estimated $1.08M and bringing the position to 121,581 shares worth $9.18M. The position accounts for 0.01% of the portfolio, ranked #864.

Amundi Asset Management US first reported a position in BMRN in Q4 2017 and has held it in 14 quarters since. The position peaked at $51.4M in Q3 2018. 531 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

Amundi Asset Management US held 121,581 shares of BioMarin Pharmaceuticals worth $9.18M as of Q1 2021.
Amundi Asset Management US bought 13,177 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $1.08M.
BioMarin Pharmaceuticals made up 0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #864 holding.
Amundi Asset Management US first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 14 quarters since.
Amundi Asset Management US's BioMarin Pharmaceuticals position peaked at $51.4M in Q3 2018.
531 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.